Plasminogen activator inhibitors

Trends in Cardiovascular Medicine

Volumn 1, Issue 3, 1991, Pages 99-102

  Schneiderman, Jacob ^a   Loskutoff, David J ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR;

HUMAN; REVIEW; THROMBOSIS;

EID: 0025738266     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/1050-1738(91)90001-U     Document Type: Short Survey

References (32)

1. Elevated levels of the rapid inhibitor of plasminogen activator (t-PAI) in acute myocardial infarction
2. The placental type plasminogen activator inhibitor, PAI 2
3. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease
4. Protease nexins: secreted proteins that regulate protease activity at or near the cell surface
5. Plasminogen activator inhibitor (PAI-1) in plasma and platelets
6. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma: identification as a multimeric form of S protein (vitronectin)
7. Elevated plasminogen activator inhibitor (PAI), a cause of thrombophilia? A study in 203 patients with familial or sporadic venous thrombophilia
8. Development of venous occlusions in mice transgenic for plasminogen activator inhibitor-1 gene
9. Changes in the plasma levels of type 1 and type 2 plasminogen activator inhibitors in normal pregnancy and in patients with severe preeclampsia
10. Plasminogen activator inhibitor types 1 and 2 in human trophoblasts
11. Localization of cells expressing t-PA, PAI-1, and urokinase by in situ hybridization in human atherosclerotic plaques and in normal rhesus monkey
12. On the usefulness of fibrinolysis variables in the characterization of a risk group for myocardial reinfarction
13. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction
14. Immunological identity of heparin-dependent plasma and urine protein C inhibitor and plasminogen activator inhibitor-3
15. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis.
16. The postoperative fibrinolytic shutdown: a rapid reverting acute phase pattern for the fast acting inhibitor of tissue-type plasminogen activator after trauma
17. Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states
18. Type 1 plasminogen activator inhibitor
19. Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits.
20. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease
21. Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease
22. Postoperative changes in the plasmatic level of tissue-type plasminogen activator and its fast-acting inhibitor-relationship to deep vein thrombosis and influence of prophylaxis
23. Plasminogen activator inhibitor 1: a new prognostic marker in septic shock
24. Regulation of type one plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells: induction by transforming growth factor-β, lipopolysaccharide, and tumor necrosis factor-α
25. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor
26. Serum-derived vitronectin influences the pericellular distribution of type 1 plasminogen activator inhibitor
27. Plasminogen activator inhibitors
28. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects
29. Interrelationship between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein (a), and established cardiovascular risk factors in a north Swedish population
30. Incidence of increased plasminogen activator inhibitor in patients with deep venous thrombosis and/or pulmonary embolism
31. Reduced human peritoneal plasminogen activating activity: possible mechanism of adhesion formation
32. Structure of the gene for human plasminogen activator inhibitor-2